Only in Titles

Search results for: Androstane-3a,17b-diol Glucuronide(5a) Antibody

paperclip

#33984827   2021/04/26 To Up

Determination of free sulfhydryl contents for proteins including monoclonal antibodies by use of SoloVPE.

F
Yuling Zhang, Pei Qi

1257 related Products with: Determination of free sulfhydryl contents for proteins including monoclonal antibodies by use of SoloVPE.

1mg1mg1mg1 mg1mg10mg1 mg100.00 ug1 mg1 mg1 mg1mg

Related Pathways

    No related Items
paperclip

#33984792   2021/05/04 To Up

Experimental efficacy of a trivalent vaccine containing porcine circovirus types 2a/b (PCV2a/b) and Mycoplasma hyopneumoniae against PCV2d and M. hyopneumoniae challenges.

T
Siyeon Yang, Taehwan Oh, Kee Hwan Park, Hyejean Cho, Jeongmin Suh, Chanhee Chae

2799 related Products with: Experimental efficacy of a trivalent vaccine containing porcine circovirus types 2a/b (PCV2a/b) and Mycoplasma hyopneumoniae against PCV2d and M. hyopneumoniae challenges.

25 mg96T1000 TESTS/0.65ml 5 G100 mg25 mg1000 tests100ul200ul1 ml

Related Pathways

    No related Items
paperclip

#33984553   2021/05/10 To Up

Burosumab treatment for fibrous dysplasia.

Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is a rare mosaic disorder of Gα activation. Fibroblast Growth Factor 23 (FGF23)-mediated hypophosphatemia is a feature of FD/MAS that has been associated with poor skeletal outcomes. Standard therapy includes oral phosphorus and vitamin D analogs; however, treatment is limited by potential adverse renal and gastrointestinal effects. Burosumab is a monoclonal antibody to FGF23 approved to treat patients with X-linked hypophosphatemia and tumor-induced osteomalacia. There is currently no safety or efficacy data to support burosumab use in patients with FD/MAS.
Anne Gladding, Vivian Szymczuk, Bethany A Auble, Alison M Boyce

1955 related Products with: Burosumab treatment for fibrous dysplasia.

2x5L 100 G0.25 mgeach50 ml50 mL96 Well 1 G1 mg250 mg

Related Pathways

paperclip

#33984507   2021/05/10 To Up

HisPhosSite: A comprehensive database of histidine phosphorylated proteins and sites.

H
Jian Zhao, Lingxiao Zou, Yan Li, Xiaofei Liu, Cong Zeng, Chen Xu, Bin Jiang, Xuejiang Guo, Xiaofeng Song

1141 related Products with: HisPhosSite: A comprehensive database of histidine phosphorylated proteins and sites.

100ul21mg0.05mg1 mg1001005250 mg1mg20 10.00 ug

Related Pathways

    No related Items
paperclip

#33984506   2021/05/10 To Up

Proteomic analysis of ubiquitinated proteins in maize immature kernels.

P
Wei Fan, Hongjian Zhen, Gang Wang

2264 related Products with: Proteomic analysis of ubiquitinated proteins in maize immature kernels.

101001mg1mg1001mg10101050 101mg

Related Pathways

    No related Items
paperclip

#33984501   2021/05/10 To Up

The PAR promoter expression system: modified lac promoters for controlled recombinant protein production in Escherichia coli.

M
Joanne Hothersall, Rita E Godfrey, Christos Fanitsios, Tim W Overton, Stephen J W Busby, Douglas F Browning

1190 related Products with: The PAR promoter expression system: modified lac promoters for controlled recombinant protein production in Escherichia coli.

2x 100ug10ìg100 10 50 10010 50 50mg100 10 20

Related Pathways

    No related Items
paperclip

#33984500   2021/05/10 To Up

Development of anti-human IgM nanobodies as universal reagents for general immunodiagnostics.

Nanobodies are the smallest antibody fragments which bind to antigens with high affinity and specificity. Due to their outstanding physicochemical stability, simplicity and cost-effective production, nanobodies have become powerful agents in therapeutic and diagnostic applications. In this work, the advantages of nanobodies were exploited to develop generic and standardized anti-human IgM reagents for serology and IgM B-cell analysis. Selection of anti-IgM nanobodies was carried out by evaluating their yields, stability, binding kinetics and cross-reactivity with other Ig isotypes. High affinity nanobodies were selected with dissociation constants (KDs) in the nM range and high sensitivities for detection of total IgM by ELISA. The nanobodies also proved to be useful for capturing IgM in the serodiagnosis of an acute infection as demonstrated by detection of specific IgM in sera of dengue virus patients. Finally, due to the lack of an Fc region, the selected nanobodies do not require Fc receptor blocking steps, facilitating the immunophenotyping of IgM cells by flow cytometry, an important means of diagnosis of immunodeficiencies and B-cell lymphoproliferative disorders. This work describes versatile anti-IgM nanobodies that, due to their recombinant nature and ease of reproduction at low cost, may represent an advantageous alternative to conventional anti-IgM antibodies in research and diagnosis.
Martina Scarrone, Andrés González-Techera, Romina Alvez-Rosado, Triana Delfin-Riela, Álvaro Modernell, Gualberto González-Sapienza, Gabriel Lassabe

1140 related Products with: Development of anti-human IgM nanobodies as universal reagents for general immunodiagnostics.

100μl100 μg100 μg96tests

Related Pathways

paperclip

#33984489   2021/05/10 To Up

Outbreak investigation of symptomatic SARS-COV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy.

In December 2020, Italy began a national immunization campaign using the BNT162b2 mRNA COVID-19 vaccine, prioritizing healthcare workers (HCWs). Immune serum from vaccinated subjects seems to (largely) retain titres of neutralizing antibodies, even against SARS-CoV-2 VOC 202012/01-lineage B.1.1.7. Here, we describe an outbreak of SARS-CoV-2 lineage B.1.1.7 infection in three HCWs in a hospital setting; two of the HCWs were fully vaccinated (i.e., had received two doses).
Daniela Loconsole, Anna Sallustio, Marisa Accogli, Angela Leaci, Antonio Sanguedolce, Antonio Parisi, Maria Chironna

2479 related Products with: Outbreak investigation of symptomatic SARS-COV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy.

100 ul2000 Units5mg20 ul500 250 m Pcs Per Pack96 tests20mg10 mg100

Related Pathways

paperclip

#33984393   2021/05/10 To Up

Development of an immunochromatographic kit to detect severe acute respiratory syndrome coronavirus 2.

The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the worldwide coronavirus disease-19 (COVID-19) pandemic, starting in late 2019. The standard diagnostic methods to detect SARS-CoV-2 are PCR-based genetic assays. Antigen-antibody-based immunochromatographic assays are alternative methods of detecting this virus. Rapid diagnosis kits to detect SARS-CoV-2 are urgently needed.
Satoshi Oshiro, Yoko Tabe, Keiji Funatogawa, Kaori Saito, Tatsuya Tada, Tomomi Hishinuma, Naeko Mizutani, Makoto Akiwa, Jun-Ichiro Sekiguchi, Takashi Miida, Teruo Kirikae

1551 related Products with: Development of an immunochromatographic kit to detect severe acute respiratory syndrome coronavirus 2.

1 mg100 assays100 assays1 mL1 module100 ug/vial1 kit(96 Wells)0.1 mg1 module

Related Pathways

paperclip

#33984384   2021/05/10 To Up

Identification of a novel bluetongue virus 1 specific B cell epitope using monoclonal antibodies against the VP2 protein.

B
Aiping Wang, Jinran Du, Hua Feng, Jingming Zhou, Yumei Chen, Yankai Liu, Min Jiang, Rui Jia, Yuanyuan Tian, Gaiping Zhang

2422 related Products with: Identification of a novel bluetongue virus 1 specific B cell epitope using monoclonal antibodies against the VP2 protein.

100ug/vial100ug100ug100.00 ug100ul100 ug100ug100ul100ug100ug100.00 ug

Related Pathways

    No related Items